Table 3.
Prognostic ability of each staging system
| Patients | linear trend χ2 test | −2 log likelihood | P-value |
|---|---|---|---|
|
All patients (n = 150) |
|
|
|
| GPS |
53.761 |
588.797 |
<0.0001 |
| mGPS |
46.707 |
601.175 |
<0.0001 |
| CLIP |
109.309 |
545.36 |
<0.0001 |
| JIS |
64.461 |
570.82 |
<0.0001 |
| BCLC |
61.89 |
577.75 |
<0.0001 |
| TNM |
41.6 |
589.84 |
<0.0001 |
|
Curative treatment group (n = 77) |
|
|
|
| GPS |
16.33 |
169.300 |
<0.0001 |
| mGPS |
5.07 |
177.93 |
0.03 |
| CLIP |
11.28 |
171.76 |
0 |
| JIS |
9.68 |
172.22 |
0 |
| BCLC |
N/O |
N/O |
0.08 |
| TNM |
N/O |
N/O |
0.09 |
|
Non-curative treatment group (n = 73) |
|
|
|
| GPS |
23.71 |
322.27 |
<0.0001 |
| mGPS |
28.815 |
322.579 |
<0.0001 |
| CLIP |
29.480 |
311.68 |
<0.0001 |
| JIS |
16.72 |
326.370 |
<0.0001 |
| BCLC |
20.98 |
321.9 |
<0.0001 |
| TNM | 16.42 | 326.7 | <0.0001 |
Abbreviations: GPS = Glasgow Prognostic Score; mGPS = modified Glasgow Prognostic Score;
CLIP = the Cancer of the Liver Italian Program; JIS = the Japan Integrated Staging score;
BCLC = the Barcelona Clinic Liver Cancer; TNM = tumor nodes metastasis classification; N/O = not obtained.